Market Place
Sourcing Support
Seastar Medical Completes FDA Enrollment For QUELIMMUNE
05 Mar 2026 //
GLOBENEWSWIRE
Seastar Medical Publishes Positive Real-World Data
09 Feb 2026 //
GLOBENEWSWIRE
Seastar Medical To Present At Noble Capital Markets Conference
29 Jan 2026 //
GLOBENEWSWIRE
Seastar Medical Announces 2026 Milestones
07 Jan 2026 //
GLOBENEWSWIRE
SeaStar Medical to Present at 2026 Biotech Showcase Investor Conf
06 Jan 2026 //
GLOBENEWSWIRE
Seastar Medical Announces 1-For-10 Reverse Split
23 Dec 2025 //
GLOBENEWSWIRE
Seastar Medical Cuts Mandatory Enrollment For QUELIMMUNE
02 Dec 2025 //
GLOBENEWSWIRE
Seastar Medical To Present At NobleCon21 Investor Conference
20 Nov 2025 //
GLOBENEWSWIRE
Seastar Medical Announces Appointment of Michael Messinger as CFO
17 Nov 2025 //
GLOBENEWSWIRE
Seastar Medical Reveals Q3 2025 Financials And Business Updates
13 Nov 2025 //
GLOBENEWSWIRE
Seastar Medical To Release Q3 Financial Results On Nov 13, 2025
05 Nov 2025 //
GLOBENEWSWIRE
SeaStar Early Positive Data for QUELIMMUNE in Pediatric AKI
29 Sep 2025 //
GLOBENEWSWIRE
SeaStar to Present QUELIMMUNE Data in Pediatric AKI at Symposium
23 Sep 2025 //
GLOBENEWSWIRE
Seastar Medical to Join HC Wainwright Global Investment Conf
04 Sep 2025 //
GLOBENEWSWIRE
SeaStar Study Projects Lower Pediatric AKI Costs, Higher Survival
02 Sep 2025 //
GLOBENEWSWIRE
SeaStar Medical`s Q2 2025 Financial Results and Business Updates
13 Aug 2025 //
GLOBENEWSWIRE
SeaStar Medical to Report Q2 Financial Results on August 13, 2025
07 Aug 2025 //
GLOBENEWSWIRE
SeaStar Hits Enrollment Milestone in Neutralize-AKI Pivotal Trial
06 Aug 2025 //
GLOBENEWSWIRE
SeaStar Medical`s $4.4M Direct Offering Priced Under Nasdaq Rules
31 Jul 2025 //
GLOBENEWSWIRE
Positive Results for SeaStar`s QUELIMMUNE in Pediatric AKI
22 Jul 2025 //
GLOBENEWSWIRE
SeaStar Medical Expands QUELIMMUNE Registry, Grows Customer Base
16 Jul 2025 //
GLOBENEWSWIRE
SeaStar Medical Announces $4 Million Direct Offering Under
10 Jul 2025 //
GLOBENEWSWIRE
SeaStar Medical Boosts QUELIMMUNE Use for Pediatric AKI Patients
08 Jul 2025 //
GLOBENEWSWIRE
SeaStar Medical Announces Positive Nasdaq Listing Determination
02 Jul 2025 //
GLOBENEWSWIRE
SeaStar Medical Reports Update on Nasdaq Listing Status
25 Jun 2025 //
GLOBENEWSWIRE
SeaStar Highlights QUELIMMUNE Adoption, Patient Story
24 Jun 2025 //
GLOBENEWSWIRE
SeaStar Medical Announces $8M Public Offering Price
20 Jun 2025 //
GLOBENEWSWIRE
AREVA Institute, SeaStar Medical Win DoD Grant for SCD Therapy
11 Jun 2025 //
GLOBENEWSWIRE
SeaStar CMS Coverage For SCD Trial In Cardiorenal Patients
28 May 2025 //
GLOBENEWSWIRE
SeaStar Medical Reports Q1 2025 Financial Results & Updates
14 May 2025 //
GLOBENEWSWIRE
SeaStar Hits Enrollment Goal for AKI Trial of SCD Therapy
13 May 2025 //
GLOBENEWSWIRE
SeaStar Medical to Report Q1 Financial Results on May 14, 2025
07 May 2025 //
GLOBENEWSWIRE
SeaStar Medical CEO Interview on Benzinga All Access Today
30 Apr 2025 //
GLOBENEWSWIRE
FDA Grants SeaStar 2 Breakthrough Tags for SCD Therapy
08 Apr 2025 //
GLOBENEWSWIRE
SeaStar Medical Reports Q4 and Full Year 2024 Financial Results
27 Mar 2025 //
GLOBENEWSWIRE
SeaStar Medical to Report Q4 and Year-End 2024 Results on March 2
24 Mar 2025 //
GLOBENEWSWIRE
SeaStar Medical Closes $6M Registered Direct Offering
03 Feb 2025 //
GLOBENEWSWIRE
SeaStar Announces 6M Registered Direct Offering Priced At Market
31 Jan 2025 //
GLOBENEWSWIRE
SeaStar Medical Adds Fifth Hospital Customer for QUELIMMUNE
27 Jan 2025 //
GLOBENEWSWIRE
SeaStar Activates 15th Site For Acute Kidney Injury Pivotal Trial
22 Jan 2025 //
GLOBENEWSWIRE
FDA Approves Study Of Seastar Device For Cardiorenal Syndrome
13 Jan 2025 //
GLOBENEWSWIRE
SeaStar Medical Ships Quelimmune To Fourth Hospital Customer
08 Jan 2025 //
GLOBENEWSWIRE
SeaStar Activates 14th Hospital for Adult AKI Pivotal Trial
23 Dec 2024 //
GLOBENEWSWIRE
SeaStar Projects Multibillion-Dollar Market Potential for Device
11 Dec 2024 //
GLOBENEWSWIRE
SeaStar Medical to Hold Business Update Call on Dec 11
04 Dec 2024 //
GLOBENEWSWIRE
SeaStar Medical Activates Hospital for Adult AKI Pivotal Trial
03 Dec 2024 //
GLOBENEWSWIRE
SeaStar Medical to Present at NobleCon20 on December 4, 2024
26 Nov 2024 //
GLOBENEWSWIRE
ISS & Glass Lewis Support SeaStar Medical’s Share Issuance Proposals
22 Nov 2024 //
GLOBENEWSWIRE
SeaStar Medical Ships 100th QUELIMMUNE Device to 3rd Hospital
15 Nov 2024 //
GLOBENEWSWIRE
SeaStar Medical Reports Q3 2024 Financial Results & Business Update
13 Nov 2024 //
GLOBENEWSWIRE
FDA Grants Breakthrough Device Designation to SeaStar Medical
06 Nov 2024 //
GLOBENEWSWIRE
SeaStar Medical Achieves Record Enrollment in Adult AKI Trial
01 Nov 2024 //
GLOBENEWSWIRE
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE
31 Oct 2024 //
GLOBENEWSWIRE
Economic Analysis Shows Cost Reduction with QUELIMMUNE Device
25 Oct 2024 //
GLOBENEWSWIRE
SeaStar Medical Enrolls Subjects in AKI Pivotal Trial
23 Oct 2024 //
GLOBENEWSWIRE
SeaStar Medical To Distribute QUELIMMUNE To Hospitals Directly
22 Oct 2024 //
GLOBENEWSWIRE
SeaStar Medical Enrollment In AKI Trial Exceeds Halfway Point
18 Oct 2024 //
GLOBENEWSWIRE
SeaStar Medical Showcases New Data On Immunomodulatory Device
15 Oct 2024 //
GLOBENEWSWIRE
SeaStar to Present at the 2024 Maxim Healthcare Virtual Summit
09 Oct 2024 //
GLOBENEWSWIRE
SeaStar Expands NEUTRALIZE-AKI Trial With Military Facilities
08 Oct 2024 //
GLOBENEWSWIRE
